RPL23AP34: A Promising Drug Target / Biomarker (G100271294)

Target Name: RPL23AP34

NCBI ID: G100271294

RPL23AP34

Other Name(s): RPL23A_8_204 | Ribosomal protein L23a pseudogene 34 | ribosomal protein L23a pseudogene 34

RPL23AP34: A Promising Drug Target / Biomarker

RPL23AP34 is a gene that encodes for a protein known as RPL23AP34. This protein is a key regulator of the Replication Protein Complex (RPC), which is responsible for ensuring the accurate replication of DNA in the human genome. Mutations in the RPL23AP34 gene have been linked to a range of genetic disorders, including mental retardation, developmental delays, and autoimmune diseases. As a result, understanding the function of RPL23AP34 and its potential as a drug target is of great interest.

The RPC is a complex of proteins that work together to ensure the proper execution of DNA replication. The RPL23AP34 protein plays a crucial role in regulating the RPC by controlling the activity of several key enzymes involved in the replication process.

One of the RPL23AP34 functions is to regulate the activity of the DNA polymerase I (DNA-PDI), which is responsible for copying the double helix DNA template to the new strand during replication. The DNA-PDI activity is regulated by the protein p21, which is a negative regulator of DNA-PDI. The RPL23AP34 protein is known to interact with p21 and prevent its binding to DNA-PDI, which allows for the proper function of DNA-PDI during replication.

Another function of RPL23AP34 is to regulate the activity of the DNA-protein complex (DPC), which is responsible for ensuring the stability of the replicated DNA fragment. The DPC is regulated by the protein DNAA1, which is a positive regulator of the DPC. The RPL23AP34 protein is known to interact with DNAA1 and prevent its binding to the DPC, which allows for the proper function of the DPC during replication.

In addition to its role in regulating the RPC, RPL23AP34 has also been shown to play a role in the regulation of cellular processes that are not directly related to DNA replication. For example, RPL23AP34 has been shown to be involved in the regulation of cell adhesion, cell migration, and the G1/S transition.

Gene Mutation and Human Health

Mutations in the RPL23AP34 gene have been linked to a range of genetic disorders. One of the most well-known is a condition called Down syndrome, which is caused by a Down syndrome chromosome 21 gene mutation. Individuals with Down syndrome have several unique features, including developmental delays, communication difficulties, and chronic self-injury.

In addition to Down syndrome, mutations in the RPL23AP34 gene have also been linked to other genetic disorders, including mental retardation, developmental delays, and autoimmune diseases. These mutations can cause a range of different symptoms, depending on the specific genetic disorder and the location of the mutation within the genome.

The Potential as a Drug Target

Given the importance of RPL23AP34 in the regulation of DNA replication and the development of genetic disorders, it is an attractive target for drug development. Studies have shown that inhibiting the activity of RPL23AP34 has the potential to treat a range of genetic disorders, including Down syndrome and other conditions associated with chromosomal abnormalities.

One approach to inhibiting the activity of RPL23AP34 is to use small molecules that bind to specific interacting regions of the protein. These small molecules can then inhibit the activity of RPL23AP34 and prevent it from regulating the RPC or the DPC.

Another approach to inhibiting the activity of RPL23AP34 is to use antibodies that recognize and bind to specific regions of the protein. These antibodies can then prevent RPL23AP34 from interacting with its regulatory partners, including p21 and DNAA1, and prevent it from regulating the RPC or the

Protein Name: Ribosomal Protein L23a Pseudogene 34

The "RPL23AP34 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL23AP34 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets